Experiences of Brief Admission From the Perspective of Family and Significant Others

Experiences Among Family Members, Carers and Significant Others of Brief Admission by Self-referral for Self-harming and Suicidal Persons: a Qualitative Study

As a result of a randomized controlled trial (NCT02985047) BA is continuously offered to persons with self-harm at risk for suicide in Skåne, Sweden. This qualitative inductive study aims to provide experiences among family members, carers and significant others of Brief Admission by self-referral for self-harming and suicidal persons based on individual semi-structured interviews. Participants will be identified through suggestion from persons with an active BA contract. Interviews, estimated to last 30-60 minutes, will be analyzed by a phenomenological hermeneutic method or by content analysis depending on richness and depth in the interviews. Findings from this study will be published.

Study Overview

• Status: Completed
• Conditions: Suicidal Ideation; Self-Harm, Deliberate; Self Injurious Behavior Without Suicidal Intent
• Intervention / Treatment: Other: Semi-structured interviews

Detailed Description

As a result of the randomized controlled trial evaluating BA in Skåne (NCT02985047), BA is since January 2019, continuously offered to persons with self-harm at risk for suicide in Skåne, Sweden. Parallel to the clinical trial qualitative interview studies have been performed on the experiences of BA, with participants during the pilot phase of the trial and among the most severely ill persons and from the viewpoint of psychiatric staff. The present study aims to complement the above-mentioned studies with analysis of real-life experiences of BA from the perspective of loved ones to persons with current access to BA. This is important since the persons close to those suffering from recurrent self-harm and suicidal ideation play an essential role in times of crisis and may beneficially contribute to motivation as well as effects of provided care.

In this qualitative inductive study individual semi-structured interviews will be held with family members, carers and significant others of persons with an active BA contract, who has given informed consent to participate. To identify potential informants, persons with an active BA contract, who have used BA within the last three months, at the wards in Lund, Malmö, Helsingborg or Kristianstad will be contacted and asked about contact information (name and telephone number) to a person close to them who may be contacted regarding inclusion in the present study. A variation of contract length (minimum one month since first signed contract) is strived for. The number of interviews will depend on the number of active contracts at the included wards and the proportion of those where potential participants may be contacted and who subsequently consent to participate, but with a maximum of 25 interviews. Interviews are estimated to be 30-60 minutes, and will be conducted in a calm place, chosen by the participant. Interviews will be performed by doctoral students in psychiatry and supervised by a senior researcher with experience of psychiatry and qualitative research. Interviews will be transcribed and analyzed by a phenomenological hermeneutic method or by content analysis depending on richness and depth in the interviews. Findings from this study will be published.

• Study Type: Observational
• Enrollment (Actual): 14

Contacts and Locations

• Study Contact: Name: Kajsa Landgren, PhD; Phone Number: +46462221880; Email: kajsa.landgren@med.lu.se
• Study Contact Backup: Name: Rose-Marie Lindkvist; Phone Number: +46462221880; Email: rose-marie.lindkvist@med.lu.se

Study Locations

• Sweden
  • Skåne
    • Lund, Skåne, Sweden, 22185
      • Psykiatri och habilitering, Region Skåne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

- Family member, carer or significant other as defined by persons with access to Brief Admission by self-referral through one of the psychiatric departments in Skåne, Sweden (Lund, Malmö, Helsingborg or Kristianstad).

Description

Inclusion Criteria:

• Family member, carer or significant other as defined by persons with access to Brief Admission by self-referral through one of the psychiatric departments in Skåne, Sweden (Lund, Malmö, Helsingborg or Kristianstad).
• At least 18 years of age.
• Able to consent to study participation through written and oral information.
• Given consent to participate

Exclusion Criteria:

• below the age of 18.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lived experiences	Data from semi-structured interviews	60 minutes

Collaborators and Investigators

• Sponsor: Region Skane
• Collaborators: Lund University
• Investigators: Principal Investigator: Sofie Westling, PhD, Region Skane

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2021
• Primary Completion (Actual): December 31, 2023
• Study Completion (Actual): December 31, 2023

Study Registration Dates

• First Submitted: July 5, 2021
• First Submitted That Met QC Criteria: July 13, 2021
• First Posted (Actual): July 14, 2021

Study Record Updates

• Last Update Posted (Estimated): January 31, 2024
• Last Update Submitted That Met QC Criteria: January 29, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Suicide; Suicidal Ideation; Self-Injurious Behavior
• Other Study ID Numbers: 2019-02557

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: The investigators have no ethical approval to share data from interviews.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No